Emerald Acquisition Ltd. bought a new stake in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 60,954 shares of the company’s stock, valued at approximately $1,302,000. Emerald Acquisition Ltd. owned approximately 0.17% of Intellia Therapeutics as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new position in Intellia Therapeutics during the second quarter valued at $313,000. Societe Generale purchased a new position in Intellia Therapeutics during the second quarter valued at $374,000. Monashee Investment Management LLC purchased a new position in Intellia Therapeutics during the second quarter valued at $425,000. Finally, Bank of New York Mellon Corp purchased a new position in Intellia Therapeutics during the second quarter valued at $462,000.
Intellia Therapeutics Inc (NASDAQ:NTLA) traded down 3.2284% during midday trading on Thursday, reaching $16.7802. The company had a trading volume of 447,216 shares. The firm’s 50-day moving average price is $19.66 and its 200 day moving average price is $21.95. Intellia Therapeutics Inc has a 12 month low of $16.07 and a 12 month high of $30.40. The firm’s market capitalization is $604.00 million.
Several research firms have weighed in on NTLA. Zacks Investment Research raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Janney Montgomery Scott began coverage on Intellia Therapeutics in a research report on Wednesday, September 28th. They issued a “buy” rating and a $29.00 target price for the company. Leerink Swann raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $32.00 target price for the company in a research report on Friday, August 5th. Jefferies Group upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Friday, August 5th. Finally, Wedbush reiterated an “outperform” rating and issued a $38.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, August 23rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $34.20.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).
Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.